R&D_Applied Pharmaceutical Science, Inc.

Research Area

Cancer Precision Therapy

Genomic and other molecular analyses across many types of cancer have revealed a striking diversity of genomic aberrations, altered signaling pathways, and oncogenic processes, which provide the comprehensive view of cancer precision therapy and pancancer study. 2018, Cell

Kinase Inhibitors

Approximately 110 novel kinases are currently being explored as targets, with the approximately 45 targets of approved kinase inhibitors represent only about 30% of the human kinome, indicating that there are still substantial unexplored opportunities for this drug class. 2021, Nature review

Mutation Induced Resistance

Drug resistance occurs primarily through four main mechanisms. Acquired drug resistance mutations most commonly affect the binding of the drug to its target. 2021, Nature review

Pipeline

Based on APS’s independent Integrated Computational Chemical Biology (ICCB) drug development platform, APS focuses on a deep understanding of cancer genetics, protein structure and function, synthetic medicinal chemistry, experiment and Computation integrated verification technology. We are seeking to develop additional therapeutic areas and next-generation precision therapies that target genetic drivers of cancer.

Target

Program

Indication

Discovery

Preclinical

IND Enabling

Phase1

Phase2

Phase3

Stage

Selective next-generation RET inhibitor

APS03118

NSCLC, MTC, and other solid tumors

IND Approved by FDA and NMPA

Pan-Kras inhibitor

APS08

Multiple solid tumors

Lead Discovery

Undisclosed synthetic lethal target

APS009

Multiple solid tumors

Lead Discovery

Undisclosed siRNA target

APS-RNA-001

Multiple solid tumors

Lead Discovery

Selective next-generation RET inhibitor

APS03118 is a second generation selective RET inhibitor independently developed by APS. Preclinical data indicated that APS03118 is RET highly selective and scarcely influence on other targets. APS03118 shows remarkable potency against various RET fusion and mutations at the nanomolar level including gatekeeper V804 ...

View details

Kras inhibitor

The oncogene RAS is the first discovered human oncogene, mainly consisting of three subtypes: KRAS, HRAS, and NRAS.

View details

APS009

The concept of synthetic lethality. This figure illustrates the concept of synthetic lethality, wherein the viability of cells is contingent upon the loss of function (LOF) of either gene A or gene B individually. However, the simultaneous LOF of gene A and gene B results in cell death, indicating synthetic lethality. ...

View details

APS-RNA-001

APS-RNA-001 is the company's first oligonucleotide therapeutics project.

View details

Clinical Trials

A Phase 1，multi-center clinical trial of APS03118 in RET positive NSCLC, MTC and other solid tumor patients is being conducted in China.

APS03118 global clinical study plan

APS is going to launch a global multi-center Phase I/II clinical trial (LASER)

APS03118 Domestic Phase I Clinical Trial is Enrolling Patients

APS plans to initiate the confirmatory phase of the LASER trial

Since the First-in-Human milestonein July, 2023, we have meticulously evaluated the safety profile and pharmacological dose of APS03118. This rigorous investigation has revealed the notable potential efficacy of this novel next-generation RET inhibitor in a study population with advanced RET-altered non-small cell lung...

2024-04-04

APS03118 Domestic Phase I Clinical Trial is Enrolling Patients

In November 2022, the China only phase I clinical study of APS03118 started patient recruitment. In this study, 35 patients with unresectable, locally advanced or metastatic solid tumors with RET mutation or fusion were recruited, regardless of gender. The study has been approved by NMPA and the ethics committee of the...

2022-12-29

APS is going to launch a global multi-center Phase I/II clinical trial (LASER)

A Phase 1/2, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APS03118 in Adult Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions (LASER).

2021-12-01

APS03118 global clinical study plan

APS03118 is the next-generation of selective RET inhibitor that independently developed by APS. APS03118 is a potential best-in-class program with stronger anti-tumor activity and better tolerability compared to other RET inhibitors in preclinical internal head-to-head studies. At present, APS03118 clinical trials has ...

2021-11-16